External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)

This is a prospective, longitudinal, single-center, non-randomized, open-label, post-market clinical feasibility study to assess the efficacy of neuromodulation therapies (SCS and DRG) for chronic pain patients with diabetes and investigate whether physical and physiological data collected from diabetic and pre-diabetic chronic pain patients is predictive of subjective patient-reported outcomes (PROs) and of adjustments in patient care. These assessments will be made prior to, during, and after the trial of the SCS or DRG system. The study will be carried out in the United States at a single site.

NCT Number	NCT05537662
Lead Sponsor	Abbott Medical Devices
Conditions	Chronic Pain
Enrollment	30 participants
Start Date	2023-06-06
Primary Completion	2025-01 (estimated)
Study Completion	2025-04 (estimated)
Updated on ClinicalTrials.gov	2024-07-12